Cancer name Triple Negative Breast Cancer
Cancer Type BRCA
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment poly(I:C)
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature PD-L1
Official Symbol CD274
Mode of action TRAN_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description As TLRagonists that stimulate IFN production are being trialed clinically, we wanted to test whether the TLR3 agonist poly(I:C) also increased PD-L1 expression. Transfection of cellswith poly(I:C) for 24 hours significantly upregulated cell surface PD-L1 expression (P > 0.05). Addition of MAR1, a type I IFNα receptor (IFNAR) blocking antibody, abrogated poly(I:C) induced PD-L1 upregulation, confirming that poly(I:C) is stimulating PD-L1 expression via type I IFN production/signaling.
PMID 28848054
Title Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC